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• Classification of Hepatic Encephalopathy 
– Covert vs Minimal 
– The brain in ACLF 
• Pathogenesis of HE 
– Ammonia and Inflammation  
• New concepts of underlying mechanisms 
– Involvement of different inflammatory cell types in HE 
• Why may HE increase the risk of death of cirrhotic 
patients? 
• Is HE truly reversible? 
• Interorgan ammonia metabolism: The basis of novel 
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Classification of HE: Clarification or 
Confusion? 
Vilstrup et al. J Hepatol 2014 










Grade 1 HE 
n=44 
 
Age (year) 59 ± 6 58 ± 10 58 ± 12 
MELD 15 ± 6 14 ± 6 16 ± 6 
Albumin (g/dL) 2.8 ± 0.7 2.9 ± 0.5 2.9 ± 0.5 
Ammonia (mol/L) 48 ± 11 61 ± 14* 62 ± 12* 
Sodium (mmol/L) 136 ± 5 136 ± 6 135 ± 5 
Creatinine (mol/L) 91 ± 60 69 ± 39 81 ± 43 
WBC count (x 109/L) 5.0 ± 2.2 6.5 ± 3.1 7.4 ± 4.8 
*p<0.05 compared with unimpaired 
Thomsen et al. Plosone 2016 
Mortality 
Thomsen et al. Plosone 2016 







Grade 1 HE 
n=44 
Infections n (%) 2 (9) 7 (18) 15 (34) 
HE n (%) 1 (4) 3 (8) 8 (18) 
Thomsen et al. Plosone 2016 


























Neut. resp. burst (%) 
 
13 ± 11 
 
13 ± 14 
 






84 ± 15 
 
81 ± 13 
 




Cause or Effect? 
Thomsen et al. Plosone 2016 
Overt Hepatic Encephalopathy 
Is there need for a Type D 
EASL/AASLD Concensus. JHEP 2014 
Adapted from Jalan et al. Gastro 2014 2015 
The severity of HE is associated with 
different short and medium term mortality 
Adapted from Cordoba J et al. J Hepatol 2014;60:275–81 
The presence of ACLF alters the natural 
history of Hepatic Encephalopathy 
*p-value comparing presence vs absence of HE in patients without ACLF  
**p-value comparing presence vs absence of HE in patients with ACLF 
Competing risk assessment 
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No ACLF + HE (n=286) 
ACLF – No HE (n=127) 
ACLF + HE (n=174) 
p<0.001** 
Time (days) 
Adapted from Cordoba J et al. J Hepatol 2014;60:275–81 
Inflammation is a key factor distinguishing HE with 
ACLF vs HE without ACLF? 






   White Cell count 









Adapted from Cordoba J et al. J Hepatol 2014;60:275–81 
Inflammation worsens 
Brain Swelling during 
Hyperammonemia but 
anatomical break down 
of Blood-Brain Barrier 
was NOT observed 
Are they neuropathologically different? 
What is the pathophysiological basis of 
HE in ACLF in humans? 
Prospective Study in ICU admitted patients 
with ACLF with an without HE 
• N=101 
• HE graded using West Haven cirteria 
• Overt HE: Defined as Grade 2 or more 
 
• Patients monitored 
– Sequential arterial ammonia 
– Inflammatory markers 
– Reverse jugular catheter to monitor oxygen saturation 
• Standard of care defined 
Sawhney et al. Liver Transplantation 2016 
The presence of HE determines the risk of death 
in ACLF patients studied prospectively (n=101) 
Sawhney et al. Liver Transplantation 2016 
Ammonia levels in overt HE (likely no ACLF) 
Ong et al. Am J Med 2003 
Ammonia levels were an independent predictor of severity of HE 
What about patients with ACLF? 
Sawhney et al. Liver Transplantation 2016 
Inflammation (WCC) 
Sawhney et al. Liver Transplantation 2016 
In ACLF and Brain oxygenation 
Sawhney et al. Liver Transplantation 2016 
The severity of hyperammonemia and jugular 
venous oxygen saturation determines risk of HE 
Sawhney and Holland-Fischer et al. AASLD 2014 










Sawhney et al. Liver Transplantation 2016 
Liver Injury 
Acute Chronic 
Acute Liver Failure Cirrhosis 
Portosystemic shunt 
(+/-) 
Type A Type B Type C 
ACLF 
Inflammation 
+ Organ Failure 
?Type D  
Where would the Type D fit in? 
Questions 
• Classification of Hepatic Encephalopathy 
– Covert vs Minimal 
– The brain in ACLF 
• Pathogenesis of HE 
– Ammonia and Inflammation  
• New concepts of underlying mechanisms 
• Why may HE increase the risk of death of cirrhotic 
patients? 
• Is HE truly reversible? 
• Interorgan ammonia metabolism: The basis of novel 





































The Ammonia Story of Hepatic Encephalopathy 
Neuropathology 
Astrocyte Dysfunction and swelling 
Astrocyte Swelling vs 
Shrinkage  
Involvement of the 
Ammonia transporter 
NKCC1 (Thrane et al. Nature Medicine, 2013; 
19, 1643–1648) 
Hadjihambi, Rose and Jalan 
Hepatology 2014 
• >98% of ammonia 
present as NH4+ 
 
• NH4+ is capable 
crossing all 
phospholipid cell 









Maximum Coma Grade 
I II III IV ICP 
42 29 29 47 17 
66 34 28 46 30 
0 40 20 56 35 
0 0 47 100 72 
0 0 0 84 65 
Inflammation and Encephalopathy 
Rolando et al, Hepatology 32, 734, 2000 
* On admission 
Resolution of infection 
24-36hr 
Inclusion into study Discharge 
Admission with infection 
 Resuscitate 
 Start antibiotics 
 Induce hyperammonemia 
Measure changes in neuropsychometry 




































Ammonia and Inflammation: 
Ammonia induced Brain edema is reduced in TLRKO 
Sharifi et al. AASLD 2014 
















































Brain Flux of Pro-Inflammatory Cytokines 
ICP: Uncontrolled during patient FU 
Wright et al. Metab Brain Dis, 2007 










PRIMING OF ORGANS + BRAIN 
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Ammonia induces spontaneous respiratory burst 
through effects on p38 MAP kinase pathway 
 p38 antagonist: 10 µM SB203580 
Shawcross and Jalan et al. Hepatology 2007 




Can Hepatic Encephalopathy produce 
Immune Failure? 
Prass et al. J Exp Med. 2009 Sep 1;198(5):725-36.  
Due to apoptotic loss of 
Lymphocytes 
 
Shift from Th-1 to Th-2 
Phenotype 
Reversed by inhibition of 
Sympathetic System 
García-Martinez R. et al 2011 
Episodes of HE lead to neurodegeneration 
What is the mechanism? 
Expression of 
Serpin-1, a marker of 
senescence is 
increased in HE 
Cortex Cerebellum 
Hippocampus 
Oria et al. EASL 2014 
Therapeutic Approaches 










PRIMING OF ORGANS + BRAIN 











Where is Ammonia metabolised in Liver 
Failure patients 
Shawcross and Jalan, Lancet 2005 












Glycerol Phenylbutyrate works by 
removing Glutamine 
Shawcross and Jalan, Lancet 2005 










Phenylacetylglutamine Excreted in the urine  
Established treatment for 
hyperammonemia in patients with urea-
cycle disorders 






Treatment of hepatic encephalopathy 
 
 
 • Primary Prophylaxis 
• Secondary Prophylaxis 
• Treatment of the Acute episode 
Can we predict which patients with 
cirrhosis will develop HE and can 









































Patients at risk, n 













































Patients at risk, n 
Short-short or short-long 
Long-long 
Romero-Gomez M et al. Ann Intern Med 2010;153:281–88 
Secondary Prophylaxis 
  









2 4 6 8 10 12 14 16 18 20 
p=0.001 
Probability of breakthrough hepatic encephalopathy 



























Rifaximin for Secondary Prophylaxis of HE: 
Recurrence 
 58% risk reduction (NNT = 4 over 6 months) 






Recurrent HE (patients - %) 




Hazard ratio with rifaximin, 0.42  








0 28 56 84 112 140 168 
Rifaximin 









Time to first recurrent HE episode Recurrent HE 































Hazard Ratio: 0.56 
95% CI: (0.32, 0.99) 
p value:0.047 






























Hazard Ratio: 0.29 
95% CI: (0.12, 0.73) 
p value:0.0086 GPB Placebo 
Time to HE event. The time to the first HE event over time is depicted for all patients (top panel; n=178), in patients 
not on rifaximin at baseline (middle panel; n=119), and in patients on rifaximin at baseline (bottom panel; n=59) 
Rockey D et al. Hepatology 2014;59:1073–83 
AMMONIA Baseline Treatment* 
Placebo 54 (34) umol/L 58 umol/L/wk 
GPB 48 (35) umol/L 46 umol/L/wk 
Glycerol phenylbutyrate reduces ammonia 
and prevents HE 
Treatment of the Acute Episode 
Treat precipitating event 
Nutrition 
Clean Bowel 
Treat precipitating factors 
Reduce ammonia: GPB; OP 
 
 In patients in whom there is no response? 
 Albumin Dialysis 
Low protein diet? 
Normal protein diet for episodic HE: results of a randomised study 
Cordoba et al. J of Hepatol 
• Outcome of HE was no 
different. 
  
• Protein synthesis was 
similar. 
 
• Those on the low-
protein diet group 
showed higher protein 
breakdown. 
Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt 
Hepatic Encephalopathy: The HELP Randomized Clinical Trial 
Rahimi et al. JAMA Intern Med. 2014;174(11):1727-1733. 


OCR-002 vs Standard of Care 
Courtesy: Genesca et al. 
Leckie, Davies and Jalan GASTROENTEROLOGY 2012;142:690–699 
J Hepatol 2013 

MARS Rx was significantly better 
Survival 
 
2 and 4 week survival were 
significantly greater in the 
responders compared with 
non-responders 






































• Classification of HE 
– Covert HE is a heterogenous entity  
– HE in ACLF should be classified separately 
• The mechanisms of the deleterious effects of 
ammonia are being redefined 
– Ammonia and inflammation are synergistic in causing HE 
– Both are targets of therapy 
• HE is not reversible and efforts to prevent 1st and 
recurrent episodes is urgently needed 
• New therapeutic strategies for HE are emerging 
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